DDInter624 DDInter463
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) resembles {v} (Disease) sarcoma
sarcoma {u} (Disease) is treated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacarbazine
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) regulates {v} (Gene) CADM1
CADM1 {u} (Gene) is upregulated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is regulated by {v} (Gene) TCTA
TCTA {u} (Gene) is upregulated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacarbazine
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) regulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is regulated by {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is downregulated by {v} (Compound) Dacarbazine
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is upregulated by {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacarbazine
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dacarbazine (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) resembles sarcoma (Disease) and sarcoma (Disease) is treated by Dacarbazine (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) regulates CADM1 (Gene) and CADM1 (Gene) is upregulated by Dacarbazine (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Dacarbazine (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is regulated by TCTA (Gene) and TCTA (Gene) is upregulated by Dacarbazine (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Zidovudine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) regulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Dacarbazine (Compound)
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is regulated by HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Dacarbazine (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is upregulated by Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine